Table 1 Baseline characteristics of patients.
Variable | All patients | Experimental group | Control group | P value |
|---|---|---|---|---|
N = 92 | N = 43 | N = 49 | ||
Age (years) | 53.3 ± 11.8 | 51.9 ± 10.8 | 54.5 ± 12.7 | 0.294 |
Gender | 0.808 | |||
Male | 80 | 37 | 43 | |
Female | 12 | 6 | 6 | |
ECOG-PS score | 0.182 | |||
0 | 32 | 18 | 14 | |
1 | 60 | 25 | 35 | |
Child–pugh classification | 0.283 | |||
A | 48 | 25 | 23 | |
B | 44 | 18 | 26 | |
BCLC stage | 0.694 | |||
B | 26 | 13 | 13 | |
C | 66 | 30 | 36 | |
HBsAg | 0.882 | |||
Positive | 67 | 31 | 36 | |
Negative | 25 | 12 | 13 | |
HBV-DNA | 0.581 | |||
Positive | 55 | 27 | 28 | |
Negative | 37 | 16 | 21 | |
Alcohol use | 0.363 | |||
Yes | 41 | 17 | 24 | |
No | 51 | 26 | 25 | |
Concomitant disease | 0.761 | |||
Hypertension | 8 | 7 | 5 | |
Diabetes | 7 | 3 | 4 | |
Coronary heart disease | 4 | 2 | 3 | |
Extrahepatic metastasis | 0.117 | |||
Yes | 35 | 20 | 15 | |
No | 57 | 23 | 34 | |
Esophageal varices | 0.248 | |||
Yes | 13 | 8 | 5 | |
No | 79 | 35 | 44 | |
Portal hypertension | 0.841 | |||
Yes | 29 | 14 | 15 | |
No | 63 | 29 | 34 | |
Macrovascular invasion | 0.975 | |||
VP0 | 51 | 24 | 27 | |
VP1-2 | 23 | 11 | 12 | |
VP3-4 | 18 | 8 | 10 | |
Alanine aminotransferase (U/L) | 37.7 ± 18.0 | 40.5 ± 18.1 | 35.3 ± 17.7 | 0.170 |
Total bilirubin (µmol/L) | 25.2 ± 17.0 | 26.2 ± 22.9 | 24.2 ± 9.3 | 0.582 |
Prothrombin time (s) | 14.5 ± 2.4 | 14.5 ± 2.6 | 14.6 ± 2.2 | 0.869 |
International normalized ratio | 1.3 ± 1.6 | 1.6 ± 2.3 | 1.1 ± 0.2 | 0.139 |
α-Fetoprotein (ng/ml) | 281.5 ± 505.7 | 195.7 ± 493.9 | 356.8 ± 508.9 | 0.127 |
PIVKA-II (mAU/mL) | 189.7 ± 342.0 | 154.5 ± 200.9 | 220.5 ± 429.4 | 0.529 |
